Goodwin Procter advised Bregal Sagemount on the deal. Bregal Sagemount announced its strategic investment in DentalXChange. Together the firms are eyeing robust strategic growth led by a […]
Bregal Sagemount’s Investment in DentalXChange
Permira’s Investment in BPL and Kedrion
Goodwin Procter advised Bio Products Laboratory and Tiancheng International Investment Limited on the deal. The shareholders of Kedrion was advised by Carnelutti and Pedersoli Studio Legale, […]
Aura Biosciences’ $75.6 Million IPO
Goodwin Procter advised Aura Biosciences on the deal. Aura Biosciences, Inc. (Nasdaq: AURA) announced its initial public offering of 5,400,000 shares of common stock at a public […]
EQRx’s Merger with CM Life Sciences III
Goodwin Procter advised EQRx on the deal while White & Case LLP advised CM Life Sciences III Inc. EQRx, Inc. announced its definitive merger agreement with CM […]
Pfizer’s $2.26 Billion Acquisition of Trillium Therapeutics
Goodwin Procter and Baker McKenzie advised Trillium Therapeutics on the deal, while Ropes & Gray LLP and Norton Rose Fulbright Canada represented Pfizer. Trillium Therapeutics (NASDAQ/TSX: […]
Ambrx Biopharma’s $126 Million IPO
Goodwin Procter LLP and JunHe advised Goldman Sachs & Co. LLC and the other underwriters on the deal, while Wilson Sonsini Goodrich & Rosati and Maples […]
Femasys’ $34.45 Million IPO
Goodwin Procter advised the underwriters on the deal, while Dechert advised Femasys. Chardan, a global investment bank, announced that it acted as lead left bookrunner in […]
Centessa Pharmaceuticals’ $330 Million IPO
Wilson Sonsini Goodrich & Rosati and Goodwin Procter LLP advised Centessa Pharmaceuticals on the deal. Centessa Pharmaceuticals, a clinical-stage company employing its innovative asset-centric business model […]